Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osavampator Maintenance of Effect in MDD
NCT07196501Phase 3Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Aug 2025
- Primary completion
- Jul 2028
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 3 trial of osavampator in major depressive disorder (MDD), sponsored by Neurocrine Biosciences. Started Aug 2025; status: recruiting.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07196501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196501.